SecBot SecBot
8-K ·Filed Aug 10, 2026

RCKT

ROCKET PHARMACEUTICALS, INC.
BULLISH
Impact 7/10
Horizonweeks Processed3mo ago SEC0001140361-26-032028
8-K Item 2.02: Earnings release
Actionable Insight ▲ Bullish

The PRV sale and KRESLADI approval remove near-term financing risk and validate the platform, but the stock's next major catalyst is the FDA alignment on completing the Danon disease pivotal trial, expected in H2 2026. Monitor for the investor webinar and regulatory update on RP-A601 in PKP2-ACM.

DirectionBullish
Confidencehigh
Horizonweeks

Drugs in focus

RCKT drug pipeline →

KRESLADI

● Neutral Named in this 8-K
Impact
Phase
Approved (FDA accelerated approval)
Time to market
Already FDA-approved (March 26, 2026); commercial launch underway
Next catalyst
None dated

What to watchKRESLADI's approval and the $180M PRV sale provide a cash runway into Q2 2028, but the drug is an ultra-orphan gene therapy with a "minimal viable launch", not a major revenue generator. Watch the company's cardiovascular pipeline (RP-A501 for Danon disease, RP-A701 for BAG3 cardiomyopathy) for future catalysts. RCKT carries heavy short interest (~25.5% of float), a squeeze risk if pipeline data hits, but the clinical hold history on RP-A501 adds risk.

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$3.50
T+0 close · Aug 10, 2026 · via day close
Latest settled
−25.43%
T+60 · $2.61
Vs SPY
−24.94%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 11 $3.50entry
  2. T+1 · 3mo ago −2.57%α −2.82% · $3.41
  3. T+5 · 3mo ago −4.57%α −4.17% · $3.34
  4. T+20 · 2mo ago +3.71%α +4.77% · $3.63
  5. T+60 · 13d ago −25.43%α −24.94% · $2.61
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Rocket Pharmaceuticals reported Q2 2026 GAAP net income of $123.2M ($1.09 basic EPS), driven by a $178.2M gain from the sale of its Priority Review Voucher (PRV), compared to a net loss of $68.9M in Q2 2025. Operating loss improved to $46.9M from $71.1M on lower R&D and G&A expenses. The company ended the quarter with $283.7M in cash, extending runway into Q2 2028, and reported positive safety data from the first three Danon disease patients in the pivotal Phase 2 trial of RP-A501.

Key Financial Metrics

EPS
−$0.15
est $0.35 · -142.9%
Rating
in line

Key Facts

  • GAAP net income of $123.2M in Q2 2026 vs net loss of $68.9M in Q2 2025, primarily due to $178.2M gain from PRV sale.
  • Cash, cash equivalents, and investments of $283.7M as of June 30, 2026, up from $188.9M at Dec 31, 2025, extending runway into Q2 2028.
  • All three initial patients in the pivotal Phase 2 trial of RP-A501 for Danon disease completed the safety observation period with no TMA, capillary leak syndrome, or other significant safety concerns.
  • KRESLADI (marnetegragene autotemcel) received FDA accelerated approval for severe LAD-I; commercial availability and patient onboarding expected to begin in Q4 2026.
  • Operating loss improved to $46.9M from $71.1M year-over-year, driven by lower R&D and G&A expenses.

Financial Impact

Net income of $123.2M vs net loss of $68.9M YoY; cash position strengthened by $94.8M sequentially to $283.7M

net incomecashoperating expenses

Risk Factors

  • KRESLADI is a first commercial launch for the company; adoption and reimbursement timelines are uncertain.
  • Danon disease pivotal trial completion depends on FDA alignment; any delays or safety signals in additional patients could reset the timeline.
  • Operating expenses, while reduced, still consume cash; the company remains pre-revenue from product sales until KRESLADI launches.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
55% bullish (20 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001140361-26-032028
Document: ef20079821_8k.htm0001140361-26-032028
Document: 0001140361-26-032028-index-headers.html0001140361-26-032028
Document: 0001140361-26-032028-index.html0001140361-26-032028
Document: 0001140361-26-032028.txt0001140361-26-032028
8-K Data (Synthetic)0001140361-26-032028

US Market Status

Market Closed · Opens in 6h 42m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 10, 2026